EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?

Epidermal growth factor receptor-tyrosine-kinase inhibitors (EGFR-TKIs) brought a significant revolution in the treatment of non-small-cell lung cancer (NSCLC). In a short period of time, EGFR-TKIs became the standard of treatment for mutation-positive, advanced stage non-squamous NSCLC. In recent y...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Onco Targets Ther
Main Authors: Milovancev, Aleksandar, Stojsic, Vladimir, Zaric, Bojan, Kovacevic, Tomi, Sarcev, Tatjana, Perin, Branislav, Zarogoulidis, Konstantinos, Tsirgogianni, Katerina, Freitag, Lutz, Darwiche, Kaid, Tsavlis, Drosos, Zissimopoulos, Athanasios, Stratakos, Grigoris, Zarogoulidis, Paul
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2015
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4610780/
https://ncbi.nlm.nih.gov/pubmed/26508876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S91627
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki